IMF and World Bank Resume Ties with Venezuela, Opening Door to Billions in Funding 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Want to cut your energy bills? Here’s how five experts are doing it 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
U.S. Stock Futures Rise as S&P 500 and Nasdaq Reach Record Highs 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
U.S.-Iran Ceasefire Uncertainty Keeps Oil Prices Under Pressure 
China's Economy Surpasses Q1 2026 Growth Forecasts 
South Korea's Capital Markets Rebound as Foreign Investors Return 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
U.S. Dollar Steadies Near Multi-Week Lows Amid Iran Peace Talk Hopes and Global Market Shifts 
Middle East Ceasefire Hopes Lift Asian Markets as Oil Prices Retreat 
Oil Prices Plunge as Strait of Hormuz Reopens Amid U.S.-Iran Ceasefire Talks 
Iran Closes Strait of Hormuz Again After Brief Reopening, Rattling Global Energy Markets 
Merck & Co. is said to be in advanced talks for the acquisition of Seagen, a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Fox Business reported that the acquisition deal could be valued at almost $40 billion. The amount could be more as the share price for Seagen is above $200 per share. The deal will help Merck & Co. with its expansion efforts as it adds a new acquisition to its cancer drug portfolio.
Currently, Merck’s highest-selling product is its Keytruda immunotherapy drug. The Rahway, New Jersey pharmaceutical company said that this drug accounted for $17.2 billion worth of its sales last year. As for Seagen, some of its best-selling products include Adcetris, which gathered total sales of $1.4 billion last year.
In any case, while Merck and Seagen are already in the advanced stage of negotiations, it was noted that there is still no assurance that they will be reaching an agreement for the sale of the latter.
Moreover, it was mentioned that any proposed deal in this negotiation is also expected to draw a close look from antitrust regulators. Both Merck and Seagen are still hoping to finally sign an agreement on or before Merck announces its second fiscal-quarter earnings, which has been scheduled for July 28.
Reuters reached out to Merck for comments regarding the acquisition reports, but it was not able to respond to the request immediately. On the other hand, Seagen was said to have declined to comment.
As of Wednesday, July 6, the companies are still discussing a price above $200 per share, and on that day, its closing share price was actually $175. It was added that Seagen has a market capitalization of $32.24 billion based on the records from Refinitiv data.
Meanwhile, industry observers believe that it will make sense if Merck & Co. is able to close its deal with Seagen for $250 or below. This is because this acquisition will definitely boost the company’s business and strengthen its portfolio through the latter’s exclusive cancer immunotherapy drug, Keytruda.
